Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran

Malaria Journal

Volumn 6, Issue , 2007, Pages

  Zakeri, Sedigheh ^a   Afsharpad, Mandana ^a   Raeisi, Ahmad ^b   Djadid, Navid Dinparast ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b Center for Diseases Management and Control Tehran   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; PRIMAQUINE; ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MDR1 PROTEIN, PLASMODIUM FALCIPARUM; MULTIDRUG RESISTANCE PROTEIN; PROTOZOAL DNA; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CODON; CONTROLLED STUDY; DOSE RESPONSE; GENE FREQUENCY; GENE ISOLATION; GENE MUTATION; HAPLOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; PREVALENCE; SINGLE DRUG DOSE; ADOLESCENT; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; ENDEMIC DISEASE; ENZYMOLOGY; GENETICS; INFANT; MALARIA FALCIPARUM; MICROBIOLOGY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE; ENDEMIC DISEASES; HUMANS; INFANT; IRAN; MALARIA, FALCIPARUM; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 38649088544     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-6-148     Document Type: Article

References (47)

1. Hospital based surveillance of malaria related paediatric morbidity and mortality in Kinshasa, Zaire. AE Greenberg M Ntumbanzondo N Ntula L Mawa J Howell F Davachi, Bull World Health Organ 1989 67 189 196 2743538
2. Impact of chloroquine resistance on malaria mortality. JF Trape G Pison MP Preziosi C Enel A Desgreés du Loû V Delaunay B Samb E Lagarde JF Molez F Simondon, C R Acad Sci III 1998 321 8 689 697 9769862
3. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodiumfalciparum in vitro. JD Chulay WM Watkins DG Sixsmith, Am J Trop Med Hyg 1984 33 325 330 6375404
4. In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level in Amazons, Brazil. WD Alecrim H Dourado MG Alecrim LF Passos E Wanssa B Albuquerque, Rev Inst Med Trop Sao Paulo 1982 24 52 53 6764290
5. Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine (Fansidar) in a refugee camp in Thailand. ES Hurwitz D Johnson CC Campbell, Lancet 1981 16 1068 1070 10.1016/S0140-6736(81)92239-X
6. In vivo assessment ofthe sensitivity of Plasmodium falciparum tosulphadoxine/pyrimethamine combinations (Fansidar) in six locationsin Tanzania where chloroquine-resistant P. falciparum hasbeen detected. VAEB Kilimali AR Mkfuya, Trans R Soc Trop Med Hyg 1985 79 482 483 10.1016/0035-9203(85)90071-9 3909553
7. Imported cases of chloroquine-resistant falciparum malaria in Iran. GH Edrissian S Shahabi E Pishva J Hajseyed-Javadi B Khaleghian M Ghorbani AM Emadi A Afshar H Saghari, Bull Soc Path Exot 1986 79 217 221 3524879
8. Monitoring of the therapeutic efficacy of chloroquine for the treatment of uncomplicated, Plasmodium falciparum malaria in Iran. A Raeisi P Ringwald O Safa A Shahbazi M Ranjbar H Keshavarze M Nateghpour L Faraji, Ann Trop Med Parasitol 2006 100 11 16 10.1179/136485906X86220 16417708
9. Assessment of the response in vivo and invitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran. GH Edrissian A Afshar A Sayedzadeh GH Mohsseni MT Satvat, J Trop Med Hyg 1993 96 237 240 8345544
10. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. DA Fidock T Nomura AK Talley RA Cooper SM Dzekunov MT Ferdig LM Ursos AB Sidhu B Naude KW Deitsch XZ Su JC Wootton PD Roepe TE Wellems, Mol Cell 2000 6 861 871 10.1016/S1097-2765(05)00077-8 11090624
11. A molecular marker for chloroquine- resistant falciparum malaria. A Djimde OK Doumbo JF Cortese K Kayentao S Doumbo Y Diourte A Dicko XZ Su T Nomura DA Fidock TE Wellems CV Plowe, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152
12. Chloroquineresistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. AB Sidhu D Verdier-Pinard DA Fidock, Science 2002 298 210 213 10.1126/science.1074045 12364805
13. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. A Djimde OK Doumbo RW Steketee CV Plowe, Lancet 2001 358 890 891 10.1016/S0140-6736(01)06040-8 11567708
14. Changing ideas on chloroquine in Plasmodium falciparum. C Sanchez M Lanzer, Curr Opin Infect Dis 2000 13 653 658 11964837
15. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confersresistance to pyrimethamine in falciparum malaria. DS Peterson D Walliker TE Wellems, Proc Nat Acad Sci USA 1988 85 9114 9118 2904149 10.1073/pnas.85.23.9114
16. Resistance to antifolate in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origin. P Wang CS Lee R Bayoumi A Djimde O Doumbo G Swedberg LD Das H Mshinda M Tanner WM Watkins PFG Sims JE Hyde, Mol Biochem Parasitol 1997 89 161 177 10.1016/S0166-6851(97)00114-X 9364963
17. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. MB Reed KJ Saliba SR Caruana K Kirk AF Cowman, Nature 2000 403 906 909 10.1038/35002615 10706290
18. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. DS Peterson WK Milhous TE Wellems, Proc Natl Acad Sci USA 1990 87 3018 3022 2183222 10.1073/pnas.87.8.3018
19. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine and sulfamethoxazole. I Khalil AM Ronn M Alifrangis HA Gabar GM Satti IC Bygbjerg, Am J Trop Med Hyg 2003 68 586 589 12812351
20. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RA Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 388 10.1086/338566 11807721
21. Mutations in dihydropteroate synthetase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. TJ Triglia JG Menting C Wilson AF Cowman, Proc Natl Acad Sci USA 1997 94 13944 13949 9391132 10.1073/pnas.94.25.13944
22. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. AO Talisuna A Nalunkuma-Kazibwe P Langi TK Mutabingwa WW Watkins EV Marck TG Egwang U D'Alessandro, Infect Genet Evol 2004 4 321 327 15374529
23. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. AO Talisuna P Langi TK Mutabingwa W Watkins E Van Marck TG Egwang U D'Alessandro, Trans R Soc Trop Med Hyg 2003 97 338 342 10.1016/S0035-9203(03)90163-5 15228255
24. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. AM Nzila EK Mberu J Sulo, Antimicrob Agents Chemother 2000 44 991 996 10722502 10.1128/AAC.44.4.991-996. 2000
25. Molecular evidence of greater selective pressure for drug resistance exerted by the long acting antifolatepyrimethamine/sulfadoxine compared with the shorter-actingchlorproguanil/dapsone on Kenyan Plasmodium falciparum. AM Nzila E Nduati EK Mberu SC Hopkins SA Monks PA Winstanley WM Watkins, J Infect Dis 2000 181 2023 2028 10.1086/315520 10837185
26. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. T Mutabingwa A Nzila E Mberu, Lancet 2001 358 1218 1223 10.1016/S0140-6736(01)06344-9 11675058
27. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in Africa adult patients infected with Plasmodium falciparum malaria parasites. LK Basco R Tahar P Ringwald, Antimicrob Agents Chemother 1998 42 1811 1814 9661026
28. Monitoring antimalarial drug resistance: making the most of the tools at hand. CV Plowe, J Exp Biol 2003 206 3745 3752 10.1242/jeb.00658 14506209
29. Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. A Djimde A Dolo A Ouattara S Diakite CV Plowe OK Doumbo, J Infect Dis 2004 190 853 855 10.1086/422758 15272415
30. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. G Snounou S Viriyakosol XP Zhu W Jarra L Pinheiro VE do Rosario S Thaithong KN Brown, Mol Biochem Parasitol 1993 61 315 320 10.1016/0166-6851(93)90077-B 8264734
31. Plasmodium falciparum detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. MT Duraisingh J Curtis DC Warhust, Exp Parasitol 1998 89 1 8 10.1006/expr.1998.4274 9603482
32. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the antimalarials mefloquine and artemisinin. MT Duraisingh P Jones I Sambou L von Seidlein M Pinder DC Warhurst, Mol Biochem Parasitol 2000 108 13 23 10.1016/S0166-6851(00)00201-2 10802315
33. Preliminary study of the response of Plasmodium falciparum to chloroquine in Sistan and Baluchistan province of Iran. GH Edrissian S Shahabi, Trans R Soc Trop Med Hyg 1985 79 563 564 10.1016/0035-9203(85)90101-4 3909559
34. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. A Heidari S Dittrich T Jelink A Kheirandish K Banihashemi H Keshavarz, Parasitol Res 2007 100 589 592 10.1007/s00436-006-0291- z 17024359
35. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. DS Peterson SS Di M Povoa VS Calvosa RV Do TE Wellems, Am J Trop Med Hyg 1991 45 492 497 1951858
36. Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. GJ Gasey M Ginny M Uranoli I Mueller JC Reeder B Genton AF Cowman, Am J Trop Med Hyg 2004 70 251 255 15031512
37. High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran. S Zakeri JP Gil S Bereckzy ND Djadid A Bjorkman, J Infect Dis 2003 187 1828 1829 10.1086/375250 12751044
38. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with Sulfadoxine-Pyrimethamine resistance. A Ahmed D Bararia S Vinayak M Yameen S Biswas V Dev A Kumar MA Ansari YD Sharma, Antimicrob Agents Chemother 2004 48 879 889 14982779 10.1128/AAC.48.3.879-889. 2004
39. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. S Biswas A Escalante S Chaiyaroj P Angkasekwinai AA Lal, Trop Med Int Health 2000 5 737 743 10.1046/j.1365-3156. 2000.00632.x 11044269
40. Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine- pyrimethamine in Sri Lanka. HC Hapuarachchi MYD Dayanath KBAT Bandara S Abeysundara W Abeyewickreme NR De Silva SY Hunt CH Sibley, Am J Trop Med Hyg 2006 74 198 204 16474070
41. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea. T Mita A Kaneko I Hwaihwanje T Tsukahara N Takahashi H Osawa K Tanabe T Kobayakawa A Bjorkman, Infect Genet Evol 2006 6 447 452 10.1016/j.meegid.2006.02.004 16600696
42. Sulfadoxine resistancein the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. P Wang M Read PFG Sims JE Hyde, Mol Microbiol 1997 23 979 86 10.1046/j.1365-2958.1997.2821646.x 9076734
43. short report: differences in dihydrofolate reductase but not dihydropteroate synthetase alleles in Plasmodium falciparum isolates from geographically distinct areas in Malaysia. J Cox-Singh R Zakaria MS Abdullah HA Rahman S Nagappan B Singh, Am J Trop Med Hyg 2001 64 28 31 11425158
44. DHFR and DHPSgenotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. A Aubouy S Jafari V Huart F Migot-Nabias J Mayombo R Durand M Bakary JL Bras P Deloron, J Antimicrob Chemother 2003 52 43 49 10.1093/jac/dkg294 12805261
45. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthetase of isolates from the Amazon region of Brazil. KF Vasconcelos CV Plowe CJ Fontes D Kyle DF Wirth LH Pereira daSilva MG Zalis, Mem Inst Oswaldo Cruz 2000 95 721 728 10.1590/S0074-02762000000500020 10998224
46. Real-Time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India. J Keen GA Farcas K Zhong S Yohanna MW Dunne KC Kain, J Clin Microbiol 2007 45 2889 2893 10.1128/JCM.02291-06 17609321
47. Widespread occurrence of the Plasmodium falciparum chloroquine resistance transporter(PFCRT) gene haplotype SVMNT in P. falciparum malaria in India. PG Vathsala A Pramanik S Dhanasekaran CU Devi CR Pillai SK Subbarao SK Ghosh SN Tiwari TS Sathyanarayan PR Deshpande GC Mishra MR Ranjit AP Dash PN Rangarajan G Padmanaban, Am J Trop Med Hyg 2004 70 256 259 15031513